Published on
February 27, 2023
- 13:45 GMT
Rhythm Pharmaceuticals Announces Acquisition of Xinvento B.V. and Portfolio of Investigational Therapeutics
- Rare disease company in preclinical development for congenital hyperinsulinism - - Acquisition is strong strategic fit with Rhythm’s rare endocrinology focus and provides meaningful new development opportunity - - Expect to initiate clinical …
Distribution channels:
Companies, Healthcare & Pharmaceuticals Industry
...
